Work

Africa cannot afford to wait for malaria treatment failure

Year: 2026

Type: article

Abstract: For more than two decades, artemisinin-based combination therapies (ACTs) have been the backbone of malaria treatment across Africa. They have saved millions of lives and averted many malaria cases. That foundation is now under threat. Artemisinin partial resistance (ART-R) is now being detected using molecular surveillance across eastern Africa, the Horn of Africa, and southern Africa. It has already been confirmed in four countries: Rwanda, Uganda, Eritrea and Tanzania, with signals reported in several neighbouring countries [1].

Source: PubMed

DOI: 10.5281/zenodo.19825248

Authors: Pindolia, Deepa, Martinez-Vega, Rosario, Uzakbayeva, Gulnaz, Ishengoma, Deus, Ngou, Olivia, Gosling, Roly

Institutions: London School of Hygiene & Tropical Medicine, Ifakara Health Institute, National Institute for Medical Research, University of California, San Francisco

Language: English

Topic: Malaria Research and Control

Subfield: Public Health, Environmental and Occupational Health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W7156371580